07:00 , Oct 8, 2015 |  BC Innovations  |  Targets & Mechanisms

Nuclear blockade unlocked

Understanding the basic biology of amyotrophic lateral sclerosis (ALS) is still the biggest barrier to a serious breakthrough in the disease, despite the fact that genetic studies have pointed to some clear culprits for a...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chromosome 9 open reading frame 72 (C9orf72)

Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) In vitro, yeast and fruit fly studies suggest restoring nucleocytoplasmic transport could help treat ALS caused by hexanucleotide repeat expansions in C9orf72. Genetic screening in yeast and Drosophila harboring the C9orf72...
00:28 , Jul 6, 2012 |  BC Extra  |  Financial News

Inbiomotion raises EUR 2 million in series A

Molecular diagnostics company Inbiomotion S.L. (Barcelona, Spain) raised EUR 2 million ($2.5 million) in a series A round led by new investor Ysios Capital. Fundacio Vila Casas and JVRisk Technologies also participated. Inbiomotion was spun...
08:00 , Jan 7, 2010 |  BC Innovations  |  Tools & Techniques

Going live with aptamers

Researchers at the Duke University School of Medicine think they have improved upon a 20-year-old technology for selecting target-specific aptamers in vitro by making it work in vivo.1 Using the approach, the group identified an...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Company News

Viral Genetics, University of Colorado deal

Viral Genetics exercised its option to acquire the remaining 56% of V-Clip it does not already own for about 18.5 million shares and about 43.9 million warrants. The shares are valued at $204,000 based on...
07:00 , Apr 10, 2008 |  BC Innovations  |  Cover Story

Metastasis, Interrupted

Two studies have clarified the roles of two different proteins in metastasis, suggesting potential new therapeutic strategies to treat cancer. One study proposes agonizing the membrane protein CD151 to prevent cancer cells from mobilizing at...
07:00 , Apr 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Company News

Viral Genetics, University of Colorado deal

Viral Genetics formed a subsidiary, V-Clip Pharmaceuticals Inc., to obtain exclusive, worldwide rights to the university's IP related to diagnosis and treatment of HIV, HCV and herpes simplex virus (HSV). Viral Genetics owns 44% of...
07:00 , Sep 10, 2007 |  BioCentury  |  Product Development

HIV pipeline

HIV pipeline Company Product Description Status Gilead/Bristol-Myers Atripla emtricitabine/tenofovir/efavirenz Once-daily fixed-dose combination tablet of GILD's Truvada emtricitabine/tenofovir and BMY's Sustiva efavirenz Mkt J&J Prezista darunavir Second-generation protease inhibitor (PI) Mkt Pfizer Selzentry (Celsentri) maraviroc...
03:56 , Feb 3, 2007 |  BC Extra  |  Clinical News

DGCR8 essential for ES cell differentiation

Researchers from the University of California, San Francisco, reported in Nature Genetics that DGCR8, a nuclear protein that binds to double-stranded RNA, is required for the biogenesis of microRNA (miRNA). The researchers created DGCR8-knockout...